Test Directory
| Test Code | |||||
| PTSAB | |||||
| Test Name | |||||
| Phosphatidylserine Autoantibody Profile | |||||
| CPT Codes | |||||
| 86148 X 3 | |||||
| Included Tests | |||||
|
|||||
| Expected Turnaround Time | |||||
| 3 - 5 days | |||||
| Clinical Utility | |||||
|
As an aid in the diagnosis of certain autoimmune thrombotic disorders, such as antiphospholipid syndrome (aPS). Antibodies to PS/PT correlate with the presence of lupus anticoagulants (LA) and this test may be useful in cases with difficult LA test interpretation. This assay may also assist in the determination of risk for thrombosis as well as obstetric complications in patients with antiphospholipid antibodies. |
|||||
| Specimen and Container Info | |||||
|
Specimen Type: Serum
Collection Container: Gold Top, Serum Separator Alternate Collection Container: Red Top, Plain Desired Specimen Volume: 1 mL |
|||||
| Collection Instructions | |||||
|
|||||
| Processing and Submission Instructions | |||||
|
|||||
| Transport Instructions | |||||
|
Transport to the laboratory refrigerated. |
|||||
| Stability Requirements | |||||
|
|||||
| Causes for Rejection | |||||
|
|||||
| Methodology | |||||
| ELISA | |||||
| Reference Intervals | |||||
|
See patient report. |
|||||
| Limitations | |||||
|
•The pathogenic mechanism of aPS-PT antibody morbidity is substantially undefined, although under investigation. To date, aPS/PT antibodies are not included among the formal laboratory classification criteria for APS but are suggested as supplemental assays. • The clinical significance of PS/PT IgG or IgM antibodies in diseases other than SLE or APS is currently under investigation. • When negative PS/PT IgG or IgM titers are found in the presence of clinical indications, a lupus anticoagulant, anticardiolipin, anti-β2 or other additional testing is indicated. • Diagnosis cannot be made on the basis of PS/PT IgG or IgM results alone. These results must be interpreted in conjunction with physical findings. • Treatment must not be initiated on the basis of a positive PS/PT IgG or IgM titer alone. Supportive clinical indications must also be present. • It is to be expected that some samples can be anticardiolipin positive and/or anti-β2 GPI positive yet PS/PT IgG or IgM negative. The anti-β2 GPI test is a specific marker of thrombotic risk. • Patients with APS can be PS/PT positive yet lupus anticoagulant, anticardiolipin or anti-β2 negative. |
|||||
| Alternate Names | |||||
|
|||||
| Reference Lab | |||||
| Labcorp Of America Holdings | |||||
| Testing Schedule | |||||
| Routine, 2 times per week | |||||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.